Reduction of insulin resistance and plasma glucose level by salsalate treatment in persons with prediabetes

Endocrine Practice

Volumn 18, Issue 6, 2012, Pages 826-833

  Faghihimani, Elham ^a   Aminorroaya, Ashraf ^a   Rezvanian, Hassan ^a   Adibi, Peyman ^b   Ismail Beigi, Faramarz ^c   Amini, Masoud ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SALSALATE;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG ERUPTION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NAUSEA; PANCREAS ISLET BETA CELL; SIDE EFFECT; TINNITUS;

EID: 84871364550     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP12064.OR     Document Type: Article

References (25)

1. Colagiuri S. Epidemiology of prediabetes. Med Clin North Am. 2011; 95: 299-307, vii.
2. Eldin WS, Emara M, Shoker A. Prediabetes: a must to recognise disease state. Int J Clin Pract. 2008; 62: 642-648.
3. Fonseca VA. Identification and treatment of prediabetes to prevent progression to type 2 diabetes. Clin Cornerstone. 2008; 9: 51-59.
4. Chiasson JL, Rabasa-Lhoret R. Prevention of type 2 diabetes: insulin resistance and beta-cell function. Diabetes. 2004; 53(suppl 3): S34-S38.
5. Arkan MC, Hevener AL, Greten FR, et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med. 2005; 11: 191-198.
6. Kim JK. Inflammation and insulin resistance: an old story with new ideas. Korean Diabetes J. 2010; 34: 137-145.
7. Shoelson SE, Lee J, Yuan M. Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance. Int J Obes Relat Metab Disord. 2003; 27(suppl 3): S49-S52.
8. Koska J, Ortega E, Bunt JC, et al. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. Diabetologia. 2009; 52: 385-393.
9. Rumore MM, Kim KS. Potential role of salicylates in type 2 diabetes. Ann Pharmacother. 2010; 44: 1207-1221.
10. Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE (TINSAL-T2D [Targeting Inflammation Using Salsalate in Type 2 Diabetes] Study Team). The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2010; 152: 346-357.
11. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science. 2001; 293: 1673-1677.
12. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994; 265: 956-959.
13. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 2005; 11: 183-190.
14. American Diabetes Association. Diagnosis and classification of diabetes mellitus [published correction appears in Diabetes Care. 2010; 33: e57]. Diabetes Care. 2010; 33(suppl 1): S62-S69.
15. WHO Expert Committee. Physical status: the use and interpretation of anthropometry; report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1995; 854: 1-452.
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18: 499-502.
17. Wallace TM, Levy JC, Mathews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004; 27: 1487-1495.
18. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006; 116: 1793-1801.
19. Gillies CL, Abrams KR, Lambert PC, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ. 2007; 334: 299.
20. Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med. 2008; 14: 222-231.
21. Bloomgarden ZT. Approaches to treatment of pre-diabetes and obesity and promising new approaches to type 2 diabetes. Diabetes Care. 2008; 31: 1461-1466.
22. Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care. 2008; 31: 289-294.
23. Kim JK, Kim YJ, Fillmore JJ, et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest. 2001; 108: 437-446.
24. Faghihimani E, Aminorroaya A, Rezvanian H, Adibi P, Ismail-Beigi F, Amini M. Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes [published online ahead of print September 22, 2011]. Acta Diabetol. PMID: 21938543.
25. Deedwania PC, Fonseca VA. Diabetes, prediabetes, and cardiovascular risk: shifting the paradigm. Am J Med. 2005; 118: 939-947.